期刊文献+

TRAIL与DDP联合应用对急性淋巴细胞白血病细胞增殖作用的影响

暂未订购
导出
摘要 目的探讨肿瘤坏死因子相关的凋亡诱导配体(TRAIL)与顺铂(DDP)联合应用抑制急性淋巴细胞白血病细胞增殖的可能机制。方法以重组载体pACCMV-TRAIL转染人T淋巴细胞白血病细胞株Jurkat,Western印迹检测细胞中TRAIL蛋白表达情况,以及单独或联合应用TRAIL及DDP处理的各组白血病细胞中,凋亡相关蛋白caspase-3、NF-κB和survivin表达水平的变化。结果DDP组及联合用药组明显抑制了survivin蛋白的表达,DDP组、TRAIL转染组及联合用药组细胞caspase-3表达上调,核因子(NF)-κB表达下降,且联合用药组作用强于单独用药组。结论TRAIL和DDP可通过caspase、NF-κB途径抑制急性淋巴细胞白血病细胞增殖,同时DDP通过对survivin的调节发挥对TRAIL的协同作用。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2009年第9期1065-1067,共3页 Chinese Journal of Gerontology
  • 相关文献

参考文献14

  • 1Yagita H,Takeda K,Hayakawa Y,et al.TRAIL and its receptors as targets for cancer therapy[J].Cancer Sci,2004;95:777-83.
  • 2Shrader M,Pino MS,Lashinger L,et al.Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT mediated X-linked inhibitor of apoptosis protein expression[J].Cancer Res,2007;67:1430-5.
  • 3Ashkenazi A,Pai RC,Fong S,et al.Safety and antitumor activity of recombinant soluble Apo2 ligand[J].Clin invest,1999;104(2):155-62.
  • 4Bucur O,Ray S,Bucur MC,et al.APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy[J].Front Biosci,2006;(11):1549-68.
  • 5Merchant MS,Yang X,Melchionda F,et al.Interferon gamma enhancesthe effectiveness of tumor necrosis factor-related apoptosis-inducingligand receptor agonists in a xenograft models of Ewing's sarcoma[J].Cancer Res,2004;64,64:8349-56.
  • 6Secchiero P,Vaccarezza M,Gonelli A,et al.TNF-related apoptosis-inducing ligand (TRAIL):a potential candidate for combined treatment of hematological malignancies[J].Curr Pharm Des,2004;10:3673-81.
  • 7Wen JH,Ramadevi N,Ngugen D,et al.Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-in duced apoptosis of human acute leukemia cells[J].Blood,2000;96(12):3900-6.
  • 8Liu Q,Hilsenbeck S,Gazitt Y.Arsenic trioxide-induced apoptosis in myeloma cells:p53-dependent G1 or G2/M cell cycle arrest,activation of caspase-8 or caspase-9,and synergy with APO2/TRAIL[J].Blood,2003;101:4078-87.
  • 9Georgakis GV,Li Y,Humphreys R,et al.Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells:induction of apoptosis and enhancement of doxorubicin-and bortezomib-induced cell death[J].Br J Haematol,2005;130:501-10.
  • 10Yee L,Fanale M,Dimick K,et al.A phase 1B safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low grade non-Hodgkin lymphoma[J].J Clin Oncol,2007;25:8078.

二级参考文献1

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部